Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
- Conditions
- Prurigo NodularisPruritus
- Interventions
- Drug: Placebo TabletsDrug: 5mg Serlopitant Tablets
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- Vyne Therapeutics Inc.
- Target Recruit Count
- 295
- Registration Number
- NCT03677401
- Locations
- 🇵🇱
Study Site 636, Bydgoszcz, Poland
🇵🇱Study Site 631, Olsztyn, Poland
🇦🇹Study Site 649, Graz, Austria
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
- Conditions
- PruritusPrurigo Nodularis
- Interventions
- Drug: Placebo TabletsDrug: 5mg Serlopitant Tablets
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- Vyne Therapeutics Inc.
- Target Recruit Count
- 285
- Registration Number
- NCT03546816
- Locations
- 🇺🇸
Study Site 529, Verona, New Jersey, United States
🇺🇸Study Site 533, Rogers, Arkansas, United States
🇺🇸Study Site 501, Aventura, Florida, United States
Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)
- Conditions
- PruritusPrurigo NodularisAtopic DermatitisPsoriasis
- Interventions
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- Vyne Therapeutics Inc.
- Target Recruit Count
- 558
- Registration Number
- NCT03540160
- Locations
- 🇺🇸
Study Site 201, East Windsor, New Jersey, United States
🇺🇸Study Site 523, Philadelphia, Pennsylvania, United States
🇺🇸Study Site 502, Dallas, Texas, United States
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis
- Conditions
- PruritusPsoriasis
- Interventions
- Drug: 5 mg Serlopitant TabletsDrug: Matching Placebo Tablets
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- Vyne Therapeutics Inc.
- Target Recruit Count
- 204
- Registration Number
- NCT03343639
- Locations
- 🇺🇸
Study Site 376, Santa Monica, California, United States
🇺🇸Study Site 213, Boise, Idaho, United States
🇺🇸Study Site 207, South Bend, Indiana, United States
Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough
- Conditions
- Refractory Chronic Cough
- Interventions
- Drug: 5 mg Serlopitant TabletsDrug: Matching Placebo Tablets
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- Vyne Therapeutics Inc.
- Target Recruit Count
- 185
- Registration Number
- NCT03282591
- Locations
- 🇺🇸
Study Site 122, Cincinnati, Ohio, United States
🇬🇧Study Site 141, Llanelli, United Kingdom
🇺🇸Study Site 123, San Diego, California, United States
A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea
- Conditions
- Papulopustular Rosacea
- Interventions
- Drug: FMX103 1.5%
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Vyne Therapeutics Inc.
- Target Recruit Count
- 504
- Registration Number
- NCT03276936
- Locations
- 🇺🇸
Foamix Investigational Site # 139, Snellville, Georgia, United States
🇺🇸Foamix Investigational Site # 138, New Albany, Indiana, United States
🇺🇸Foamix Investigational Site # 211, Arlington Heights, Illinois, United States
A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris
- Conditions
- Acne Vulgaris
- Interventions
- Drug: FMX101Drug: Vehicle Foam
- First Posted Date
- 2017-09-01
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Vyne Therapeutics Inc.
- Target Recruit Count
- 1488
- Registration Number
- NCT03271021
- Locations
- 🇺🇸
Foamix Investigational Site #403, Los Angeles, California, United States
🇺🇸Foamix Investigational Site #330, Dublin, Ohio, United States
🇺🇸Foamix Investigational Site #340, Fort Smith, Arkansas, United States
A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
- Conditions
- Facial Papulopustular Rosacea
- Interventions
- Drug: Vehicle foamDrug: FMX103 minocycline foam 1.5%
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Vyne Therapeutics Inc.
- Target Recruit Count
- 751
- Registration Number
- NCT03142451
- Locations
- 🇺🇸
Foamix Investigational Site #155, Los Angeles, California, United States
🇺🇸Foamix Investigational Site #144, Miami Lakes, Florida, United States
🇺🇸Foamix Investigational Site # 142, West Palm Beach, Florida, United States
Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- Vyne Therapeutics Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT02975271
- Locations
- 🇺🇸
Study Site 409, Lincoln, Nebraska, United States
🇺🇸Study Site 403, Tampa, Florida, United States
🇺🇸Study Site 413, Seattle, Washington, United States
Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
- Conditions
- PruritusAtopic Dermatitis
- Interventions
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- Vyne Therapeutics Inc.
- Target Recruit Count
- 484
- Registration Number
- NCT02975206
- Locations
- 🇺🇸
Study Site 364, Glendale, Arizona, United States
🇺🇸Study Site 352, Berlin, New Jersey, United States
🇺🇸Study Site 366, Fountain Valley, California, United States